1. Home
  2. TNGX vs AISPW Comparison

TNGX vs AISPW Comparison

Compare TNGX & AISPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • AISPW
  • Stock Information
  • Founded
  • TNGX 2014
  • AISPW 2006
  • Country
  • TNGX United States
  • AISPW United States
  • Employees
  • TNGX N/A
  • AISPW N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • AISPW Blank Checks
  • Sector
  • TNGX Health Care
  • AISPW Finance
  • Exchange
  • TNGX Nasdaq
  • AISPW Nasdaq
  • Market Cap
  • TNGX 351.2M
  • AISPW N/A
  • IPO Year
  • TNGX N/A
  • AISPW N/A
  • Fundamental
  • Price
  • TNGX $5.44
  • AISPW $1.89
  • Analyst Decision
  • TNGX Strong Buy
  • AISPW
  • Analyst Count
  • TNGX 6
  • AISPW 0
  • Target Price
  • TNGX $12.20
  • AISPW N/A
  • AVG Volume (30 Days)
  • TNGX 3.9M
  • AISPW 78.2K
  • Earning Date
  • TNGX 08-06-2025
  • AISPW 04-02-2025
  • Dividend Yield
  • TNGX N/A
  • AISPW N/A
  • EPS Growth
  • TNGX N/A
  • AISPW N/A
  • EPS
  • TNGX N/A
  • AISPW N/A
  • Revenue
  • TNGX $40,990,000.00
  • AISPW $17,978,226.00
  • Revenue This Year
  • TNGX N/A
  • AISPW N/A
  • Revenue Next Year
  • TNGX N/A
  • AISPW N/A
  • P/E Ratio
  • TNGX N/A
  • AISPW N/A
  • Revenue Growth
  • TNGX 10.09
  • AISPW N/A
  • 52 Week Low
  • TNGX $1.03
  • AISPW $0.18
  • 52 Week High
  • TNGX $12.02
  • AISPW $3.00
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 74.98
  • AISPW N/A
  • Support Level
  • TNGX $4.60
  • AISPW N/A
  • Resistance Level
  • TNGX $5.63
  • AISPW N/A
  • Average True Range (ATR)
  • TNGX 0.56
  • AISPW 0.00
  • MACD
  • TNGX -0.05
  • AISPW 0.00
  • Stochastic Oscillator
  • TNGX 85.47
  • AISPW 0.00

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About AISPW Airship AI Holdings Inc.

Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture.

Share on Social Networks: